Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for BCG-unresponsive NMIBC.

CR at 6 months: 13% of UroAmp+ vs 71% of UroAmp- at baseline (P<0.001).

Eur Urol 2025;88(5):430-434. SWOG S1605.PubMed 40404526